TNFRSF1B and neoplasm: Our in vitro study reveals that TNFR2 antibody antagonism, despite advanced disease and diverse treatment regimens was effective in directly killing TNFR2+ tumor cells, eliminating high numbers of TNFR2+ Tregs, permitting the expansion of Teff, and restoring Tregs/Teff ratios.